You are here: Industry Insights > CDMO

News List

Bora Group announce the rebranding of Yuta Health to Bora Health prnasia
July 06, 2021
Leading Taiwan, China-based contract development and manufacturing organization (CDMO) Bora Group today announced a name change for its subsidiary, currently Yuta Health, to Bora Health Inc. as part of an overall plan to integrate its distribution operati
Viralgen opens expanded AAV manufacturing facility in Spain firstwordpharma
July 06, 2021
The CDMO's fivefold capacity increase will provide early preclinical through to commercialisation support
Avid Bioservices Appoints Esther M. Alegria to Board contractpharma
July 05, 2021
Avid Bioservices, Inc., a dedicated biologics CDMO, has appointed Esther M. Alegria, Ph.D., as an independent member of the company’s board of directors.
Hermes Pharma Announces Spin-out from Hermes Arzneimittel contractpharma
July 05, 2021
CDMO specializes in the development and manufacture of user-friendly oral dosage forms for healthcare companies around the world.
Fujifilm Invests $850M to Expand Biologics Capabilities contractpharma
July 02, 2021
Investment in CDMO business to add development and manufacturing capacity in US and UK.
Fujifilm Diosynth Biotechnologies to expand biologics manufacturing capacity cphi-online
July 01, 2021
As part of $850 million investment package, CDMO will double US cell culture production for recombinant vaccines and increase UK gene therapy production tenfold.
WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus contractpharma
June 30, 2021
The CDMO is bringing about 500 jobs to Middletown, site expected to open in 2024.
Lonza to invest in mid-scale API manufacturing expansion at Chinese facility cphi-online
June 30, 2021
The expansion of mid-scale capacity will enable the company to offer a smooth transition between early-phase and large-scale commercial production.
WuXi STA to build second US pharma manufacturing site at Middletown cphi-online
June 30, 2021
Facility is expected to come online in 2024 and will feature testing laboratories, manufacture of active pharmaceutical ingredients and manufacture and packaging of solid dosage pharmaceuticals and sterile products.
Genezen begins construction of cGMP lentiviral production facility cphi-online
June 28, 2021
Genezen has made a start on turning its new multiphase master plan for a 75,000-sq. ft cGMP-compliant lentiviral vector production facility into reality.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page